BCRB 2018

Immune Checkpoint Inhibitors and Radiotherapy: key unanswered questions • Disease setting - second line/refractory patients or 1 st line? • Patient selection - use of biomarkers(e.g. PD-L1, high mutation burden) • Radiotherapy schedule - radiation type - dose/fractionation - target volume • Immune checkpoint inhibitors - which ICI? At T-cells or tumor cell level? - sequentialy, concomitantly, or both? - for how long?

ESTRO 2018

BeSTRO, September 2018